HC Wainwright Comments on Atossa Genetics FY2030 Earnings

Atossa Genetics Inc. (NASDAQ:ATOS) – Stock analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Atossa Genetics in a research note issued on Thursday, March 26th. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($0.15) per share for the year. HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Atossa Genetics’ current full-year earnings is ($0.22) per share.

Several other equities analysts also recently weighed in on ATOS. Ascendiant Capital Markets lifted their target price on Atossa Genetics from $116.25 to $120.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atossa Genetics in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Atossa Genetics has an average rating of “Hold” and an average target price of $68.33.

Atossa Genetics Price Performance

NASDAQ:ATOS opened at $4.72 on Friday. Atossa Genetics has a one year low of $3.76 and a one year high of $19.35. The business has a fifty day moving average price of $5.71 and a 200-day moving average price of $9.93. The firm has a market capitalization of $40.64 million, a price-to-earnings ratio of -1.31 and a beta of 1.42.

Institutional Investors Weigh In On Atossa Genetics

Hedge funds have recently made changes to their positions in the company. Ameriprise Financial Inc. bought a new position in shares of Atossa Genetics during the 2nd quarter valued at approximately $2,468,000. Renaissance Technologies LLC increased its position in Atossa Genetics by 33.2% in the fourth quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock worth $1,217,000 after purchasing an additional 514,175 shares during the last quarter. Jane Street Group LLC purchased a new stake in Atossa Genetics during the second quarter valued at $381,000. Qube Research & Technologies Ltd raised its stake in Atossa Genetics by 357.4% during the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock valued at $346,000 after purchasing an additional 325,340 shares in the last quarter. Finally, GSA Capital Partners LLP lifted its position in Atossa Genetics by 509.0% during the third quarter. GSA Capital Partners LLP now owns 310,754 shares of the company’s stock valued at $269,000 after purchasing an additional 259,725 shares during the last quarter. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.